I-VAC
Toolkit

Last Updated August 23, 2023

COVID-19 VACCINE ADMINISTRATION
SELF-GUIDED EDUCATION MODULES

This toolkit is specifically designed to aid clinicians and healthcare organizations in developing effective tactics for the incorporation of COVID-19 vaccination into routine clinical workflows. This toolkit is not meant to replace required federal or state trainings, but to act as supplemental information to help drive more efficient vaccine implementation throughout Illinois.

The information provided within these toolkits and on this landing page was last updated on August 23, 2023.

This Toolkit Includes Information and Resources On:

  • COVID-19 vaccine administration and distribution (I-CARE, working with local health departments, etc.)
  • Operational issues
  • Handling and preparation of COVID-19 vaccines
  • Post-vaccine process
  • Implementing COVID-19 vaccine mandates in your workplace
  • Strategies for overcoming vaccine hesitancy through culturally and linguistically appropriate methods
  • How to use data to support vaccine uptake

HOW TO USE THIS TOOLKIT

Download the complete toolkit or individual sections based on your needs. Each toolkit section includes an interactive PDF with live links to key resources and source material.

All resources and source material links for each toolkit section can be found under the “Resources” portion of this page, organized by section and page number.

Woman Being Vaccinated

RESOURCE LINKS

If you are using the printed version of the self-guided COVID-19 vaccination toolkit, please use the resource guide below to view all corresponding resources and source material by section. Here you will find all the links to each resource referenced within the toolkit.

5-5

FDA approved treatments

CDC‭: ‬COVID-19‭ ‬vaccination and MIS-C and MIS-A

5-6

Recommended Action(s): same type of COVID-19 vaccine

Recommended Action(s): COVID-19‭ ‬vaccination and MIS-C and MIS-A

Recommended Action(s): COVID-19 vaccination and myocarditis and pericarditis

5-7

Appendix E

FDA EUA fact sheets

5-8

Clinical Immunization Safety Assessment COVIDvax

Appendix D

Frequently Asked Questions

Managing Anaphylaxis

5-9

CDC: Use of COVID-19 Vaccines in the United States

CDC: Contraindications and Precautions

Illinois.gov: Vaccination Eligibility

5-10

CDC’s latest recommendations

5-11

FDA EUA

CDC: Scheduling and Dosing Guidance for Immunocompromised Population

5-12

CDC: Scheduling and Dosing Guidance for Immunocompromised Population

5-13

CDC: Scheduling and Dosing Guidance for Immunocompromised Population

5-14

CDC: Scheduling and Dosing Guidance for Immunocompromised Population

5-15

CDC: COVID-19 Immunization Schedule

COVID-19 Vaccine Interim COVID-19 Immunization Schedule for 6 Months of Age and Older

CDC: Scheduling and Dosing Guidance for Immunocompromised Population

5-16

‭‬Vaccine Adverse Event Reporting System‭ (‬VAERS‭)‬

5-17

Interchangeability of COVID-19‭ ‬vaccines

5-18

CDC: Use of COVID-19 Vaccines in the United States

CDC: COVID-19 Vaccine Boosters

CDC: Updates to the Evidence to Recommendation Framework: Pfizer-BioNTech and Moderna COVID-19 vaccine booster doses

5-19

Age transition guidance

Timing‭, ‬spacing‭, ‬and interchangeability of COVID-19‭ ‬vaccines

COVID-19 Vaccine: Vaccine Administration Competencies Assessment Form-February 28, 2021

5-20

For supplementary material on Intramuscular Injection Children 7 through 18 years of age please follow this PDF.

CDC: Vaccine Administration: Needle Gauge and Length

5-21

CDC: Use of COVID-19 Vaccines in the United States

Timing‭, ‬spacing‭, ‬and interchangeability of COVID-19‭ ‬vaccines

5-22

CDC: How to Increase COVID-19 Vaccination upon Discharge from Hospitals, Emergency Departments & Urgent Care Facilities

5-23

From the CDC: There is no VIS for COVID-19 vaccines authorized under an EUA. Instead, the FDA-issued EUA Fact Sheet for Recipients and Caregivers for each COVID-19 vaccine must be used.

CDC: Healthcare Providers/ Professionals

5-24

CDC: Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination

5-26

IDPH Account Portal

IDPH: Vax Verify

5-30

Suburban Cook County In-Home COVID-19 Vaccination Contact Form

5-31

Far South Region – Protect Chicago at Home Program

Near South Region – Protect Chicago at Home Program

North/Central Region – Protect Chicago at Home Program

Northwest Region – Protect Chicago at Home Program

Southwest Region – Protect Chicago at Home Program

West Region – Protect Chicago at Home Program

5-32

DuPage County COVID-19 Vaccine Registration

5-35

U.S. COVID-19 Vaccine Product Information

Moderna

6‭ ‬Months Through 5‭ ‬Years of Age Bivalent Moderna COVID-19‭ ‬Vaccine Standing Orders for Administering Vaccine

6‭ ‬Years of Age and Older Bivalent Moderna COVID-19‭ ‬Vaccine Standing Orders for Administering Vaccine

Pfizer

6‭ ‬Months Through 4‭ ‬Years of Age Bivalent Pfizer BioNTech COVID-19‭ ‬Vaccine Standing Orders for Administering Vaccine‭ ‬

5‭ ‬Years of Age and Older Bivalent Pfizer-BioNTech COVID-19‭ ‬Vaccine Standing Orders for Administering Vaccine

Novavax

Novavax COVID-19‭ ‬Vaccine‭ (‬Monovalent‭) ‬Standing Orders for Administering Vaccine to Persons 12‭ ‬Years of Age and Older

6-3

Pfizer Local & Systematic Reactions

Moderna Local & Systematic Reactions

Novavax Local & Systematic Reactions

6-4

NIH: Q&A: COVID-19, Vaccines, and Myocarditis

6-5

CDC: Table 1

CDC: Update on myocarditis following mRNA COVID-19 vaccination

CDC: Recommendations for Pfizer-BioNTech and Moderna COVID-19 Vaccine Primary Series in Children 6 Months through 5 Years Old

6-7

CDC: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination

6-8

CDC Center for Preparedness and Response

CDC: Pfizer/BioNTech BNT162b2 (COVID-19 Vaccine, mRNA) Vaccine –in Individuals 5 to <12 Years of Age

6-9

VAERS: Writable PDF Form

VAERS: Upload Completed Writable PDF Form

CDC: Reporting Adverse Events Following Vaccination

6-10

CDC: Preventing Vaccine Administration Errors

6-11

CDC: Considerations for Timing of COVID-19 Vaccination in Relation to Immunosuppressive Therapies

6-13

CDC: Table 2

CDC: Table 3

6-16

CDC: COVID-19 Vaccine Administration Errors and Deviations

6-17

CDC: Science Brief

CDC: Morbidity and Mortality Weekly Report, January 14, 2022

6-19

Pfizer-BioNTech COVID-19 Vaccine

Moderna COVID-19 Vaccines

Novavax COVID-19 Vaccine, Adjuvanted

6-20

COVID-19 Vaccines for Moderately or Severely Immunocompromised People

6-21

CDC: Use of COVID-19 Vaccines in the United States

Recommended Actions: Table 1

6-22

Recommended Actions: Table 1

CDC: Use of COVID-19 Vaccines in the United States

 6-23

CDC: Use of COVID-19 Vaccines in the United States

6-24

CDC: Emergency Use Instructions (EUI) Fact Sheet for Recipients and Caregivers: Pfizer-BioNTech COVID-19 Vaccine for Primary, Additional, and/or Booster Doses

6-25

CDC: COVID-19 Vaccines While Pregnant or Breastfeeding

6-26

January 2022 Study

2022 MMWR Study

2021 MMWR Study

CDC: COVID-19 Vaccines While Pregnant or Breastfeeding

ACOG Guidelines

6-28

Illinois.gov Guidance Affirming Non-Discrimination in Medical Treatment

CDC: People with Disabilities

AAP: COVID-19 Vaccination for Children and Youth with Developmental Disabilities

CDC’s Website

AAP’s Website